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SUMMARY  
 Stroke is a leading cause of death worldwide and the commonest cause of long-term disability 
amongst adults, more particularly in patients with diabetes mellitus and arterial hypertension. 
Increasing evidence suggests that disordered physiological variables following acute 
ischaemic stroke, especially hyperglycaemia, adversely affect outcomes. Post-stroke 
hyperglycaemia is common (up to 50 % of patients) and may be rather prolonged, regardless 
of diabetes status. A substantial body of evidence has demonstrated that hyperglycaemia has a 
deleterious effect upon clinical and morphological stroke outcomes. Therefore, 
hyperglycaemia represents an attractive physiological target for acute stroke therapies. 
However, whether intensive glycaemic manipulation positively influences the fate of 
ischaemic tissue remains unknown. One major adverse event of management of 
hyperglycaemia with insulin (either glucose-potassium-insulin infusions or intensive insulin 
therapy) is the occurrence of hypoglycaemia, which can also induce cerebral damages. Novel 
insights into post-stroke hyperglycaemia management are derived from continuous glucose 
monitoring systems (CGMS). This article aims to describe the adverse effects of 
hyperglycaemia following acute ischaemic stroke and the risk associated to iatrogenic 
hypoglycaemia, to summarise the evidence from current glucose-lowering treatment trials and 
to show the usefulness of CGMS in both nondiabetic and diabetic patients with acute stroke. 




Les accidents vasculaires cérébraux (AVC) sont une cause fréquente de mortalité et 
d’invalidité au long cours dans la population adulte, en particulier parmi les patients avec 
diabète sucré et hypertension artérielle. De nombreuses observations ont montré que les 
perturbations des fonctions physiologiques secondaires à l’AVC, et tout spécialement 
l’hyperglycémie, affectent défavorablement le pronostic. L’hyperglycémie post-AVC est  
fréquente (touchant jusqu’à 50 % des patients) et peut être relativement prolongée, que le 
sujet soit diabétique ou non. Il est démontré que l’hyperglycémie exerce des effets délétères à 
la fois sur la récupération clinique et sur l’évolution des lésions cérébrales évaluées par 
l’imagerie médicale. Dès lors, l’hyperglycémie représente une cible physiologique 
intéressante dans la prise en charge des AVC.  Cependant, il reste à apporter les preuves 
qu’une manipulation intensive de la glycémie influence positivement le pronostic cérébral. En 
effet, un événement indésirable grave de la correction de l’hyperglycémie par l’insuline (que 
ce soit par une perfusion combinée « glucose-potassium-insuline » ou par une 
insulinothérapie intraveineuse intensive) est la survenue d’une hypoglycémie qui, elle-même, 
peut entraîner des dommages cérébraux graves. Aussi, la détection et le traitement de 
l’hyperglycémie post-AVC pourraient bénéficier du recours à un système d’enregistrement 
continu des concentrations de glucose (CGMS). Cet article a pour but de rappeler brièvement 
les conséquences d’une hyperglycémie aiguë post-AVC et les risques associés à une 
hypoglycémie iatrogène, de résumer les principales données des essais cliniques qui ont tenté 
de contrôler l’hyperglycémie post-AVC et de décrire l’utilité des systèmes CGMS chez les 
patients avec ou sans diabète exposés à un AVC.  
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1. INTRODUCTION  
 Stroke is one of the most prevalent disabling disorders in western countries and has 
many similarities with myocardial infarction [1]. Several aspects of physiology, notably blood 
pressure, body temperature, blood oxygen saturation, and blood glucose, may be altered after 
an ischaemic stroke or an intracerebral hemorrhage. Patients with acute ischaemic stroke 
frequently test positive for hyperglycaemia, which is associated with a poor clinical outcome 
[2-4]. Most studies showed the deleterious effect of early hyperglycaemia, especially in 
patients with nonlacunar focal or global ischaemia [5]. This association between poor 
glycaemic control and an unfavourable prognosis is particularly evident in patients with 
persistent hyperglycaemia, patients without a known history of diabetes mellitus, and patients 
with cortical infarction [6]. It is well established that the management of patients in the stroke 
care unit improves outcome. How is it achieved remains, however, unclear. One may 
hypothesize that closed monitoring and maintenance of physiological homeostasis, including 
glucose levels, could contribute to this benefit [7]. 
 In a broader context, hyperglycaemia in critically ill patients has been shown to be 
associated with increased morbidity and mortality. An astounding 42% relative risk reduction 
in mortality in surgical intensive care unit (ICU) patients has been reported in a single centre 
study when blood glucose was tightly controlled between 4.5 and 6.1 mmol/l with insulin 
infusions [8]. In a subsequent study, the same group reported the absence of mortality benefit 
of intensive insulin therapy in medical ICU patients, except in a subgroup of patients 
requiring critical care for 3 or more days [9]. While the importance of glucose control in this 
ICU population is well recognized, many questions remain, including the external validity of 
these single centre trials, the feasibility and safety of intensive insulin therapy outside the 
context of a clinical trial, and the most appropriate target for glycaemic control in such 
critically ill patients. Indeed, two other trials of intensive insulin therapy reported 
unacceptably high rates of severe hypoglycaemia, leading to the premature interruption of one 
of them [10,11]. This was confirmed by the recent observations of the multi-national NICE-
SUGAR, a large study  that randomized 6104 ICU patients to tight glycaemic control (4.5– 
6.0 mmol/l) or conventional control (8.0–10.0 mmol/L). An increase in mortality at 90 days 
was observed with intensive versus conventional glucose control (27.5 vs. 24.9%; odds ratio 
1.14; P = 0.02) [12]. Thus, there is growing debate over the value of intensive insulin therapy 
in critically ill patients. Available trials have been performed in general medical or surgical 
ICUs, and these results may not be directly applicable to individuals with severe acute brain 
disease. Indeed, patients with acute stroke may have heightened susceptibility to 
hyperglycaemia and hypoglycaemia [13]. Therefore, considering the well known 
susceptibility of cerebral tissue to glucose changes [14,15], the influence of acute variations of 
plasma glucose levels in patients with brain injuries certainly deserves careful investigation 
[7]. If there is evidence that hyperglycaemia can increase the likelihood of poor outcomes 
after stroke, including among patients receiving tissue plasminogen activator [16], the role of 
diabetes and hyperglycaemia is difficult to investigate due to the heterogeneous nature of 
diabetes/hyperglycaemia in regard to the site of ischaemia, the degree of vasculopathy, and 
the state of reperfusion.  
 The main aims of the present review are : a) to analyze the relationship between 
hyperglycaemia and stroke outcomes; b) to describe the potential risk of iatrogenic 
hypoglycaemia in stroke patients; c) to consider the possible contribution of continuous 
glucose monitoring system (CGMS) in stroke unit; and d) to conclude with some clinical 
recommendations. 
 
2. STROKE-ASSOCIATED HYPERGLYCAEMIA 
 
 The phenomenon of increased glucose levels after acute stroke was already described 
in 1976 [17]. A neuroendocrine stress response and an inflammatory response may play a role 
in generating hyperglycaemia, which may be attributed to several underlying mechanisms : a 
non-specific reaction to acute stress and tissue injury with the associated autonomic, hormonal 
and metabolic alterations; uncovering of underlying latent diabetes by the acute stroke; 
increased secretion of growth hormone due to stroke-induced hypothalamic dysfunction; and 
irritation of the glucose regulatory centres in the hypothalamus and brain stem by blood-laden 
cerebrospinal fluid or local ischaemia [17]. One study involving nondiabetic patients 
demonstrated a rise in median blood glucose level from 5.9 mmol/L at 2.5 h to 6.2 mmol/L at 
6 h poststroke [18]. Indeed, poststroke hyperglycaemia is a frequent phenomenon, with up to 
50% of the patients having an initial blood glucose of above 6.0–7.0 mmol/L [19]; notably, 
such glucose levels, in the fasting state, would be consistent with a pre-diabetic state [20]. 
Hyperglycaemia appears to be associated with more severe stroke, as assessed either with a 
clinical stroke scale or by brain lesion volume measurement. Post-stroke hyperglycaemia has 
been associated with poor outcome [21], but seems to particularly affect outcome in patients 
without diabetes. In a meta-analysis, the relative risk of in-hospital 30-day mortality in 
patients with admission hyperglycaemia (>6.1–7.0 mmol/L) was 3.28 (95% CI 2.32 to 4.64) 
in ischaemic stroke patients without diabetes, but not significantly increased in patients with 
diabetes [22]. This observation may suggest that hyperglycaemia per se is a marker of the 
severity of the stroke rather than a real risk factor. Consequently, the poor outcomes among 
patients with hyperglycaemia may in part reflect the seriousness of the vascular event itself. 
Alternatively, diabetes is associated with microcirculatory abnormalities in the brain, 
including arteriovenous shunting and a reduction in glucose transport across the blood-brain 
barrier. These processes would reduce the delivery of glucose from the blood to the brain of a 
patient with diabetes, thus possibly protecting cerebral tissue from high glucose levels after 
acute stroke. Nevertheless, hyperglycaemia has a particularly potent adverse effect after 
thrombolysis, also in patients with diabetes [23]. Hyperglycaemic patients more commonly 
develop intracerebral hemorrhage after thrombolysis and have overall poorer clinical and 
radiological outcome [24]. Hyperglycaemic patients are also less likely to recanalise with 
thrombolysis. Even if recanalization occurs, hyperglycaemic patients are more likely to 
deteriorate, particularly if hyperglycaemia occurs early after recanalization.  So even if the 
mechanisms of cerebral glucotoxicity remain unclear, it seems to be logical to propose early 
management of hyperglycaemia in patients presenting acute stroke.  
 Unfortunately, there are no relevant scientific data proving a clear-cut efficacy of 
managing hyperglycaemia in acute stroke. A few exploratory randomised trials showed  that 
glucose-potassium-insulin (GKI) infusions can be safely administered to acute stroke patients 
with mild to moderate hyperglycaemia producing a physiological but attenuated glucose 
response to acute stroke, the effectiveness of which remains to be elucidated [25,26]. The 
large multicentre trial called “GIST-UK trial » (for Glucose Insulin in Stroke Trial) aimed to 
demonstrate whether treatment with GKI infusions to maintain euglycaemia immediately after 
the acute event reduces death at 90 days [27]. The trial was stopped due to slow enrolment 
after 933 patients were recruited. For the intention-to-treat data, there was no significant 
reduction in mortality at 90 days (GKI vs control: odds ratio 1.14; 95% CI 0.86-1.51; p=0.37). 
There were no significant differences for secondary outcomes either. In the GKI group, 
overall mean plasma glucose and mean systolic blood pressure were significantly lower than 
in the control group (mean difference in glucose 0.57 mmol/L, p<0.001; mean difference in 
blood pressure 9.0 mmHg, p<0·0001). This neutral result does not prove inefficacy of acute 
glucose control as acute blood pressure changes may be a confounding factor, the study was 
underpowered, glucose-lowering therapy was administered relatively late after ictus and, 
perhaps more importantly, GKI infusions achieved only modest decrements in glucose levels. 
A recent randomised, placebo-controlled trial of GKI infusion in patients with blood glucose 
> 7 mmol/L within 24 hours of ischaemic stroke measured infarct growth assessed by 
magnetic resonance imaging (MRI) between baseline and day 7 as primary endpoint and brain 
lactate concentrations with magnetic resonance spectroscopy [28]. GKI infusions lowered 
blood glucose (approximately 5.6 mmol/L versus 7.0 mmo/L in control subjects from 6 to 12 
hours post intervention) and attenuated an increase in brain lactate, but did not affect cerebral 
infarct growth. On the contrary, exploratory analysis found that GKI therapy was associated 
with greater infarct growth in patients with persistent arterial occlusion, and with a high 
incidence of asymptomatic hypoglycaemia (< 4 mmol/L in 76 % of patients; almost 50 % of 
GKI patients required intravenous dextrose infusion) 
 More substantial reductions in plasma glucose concentrations can be achieved using 
intensive intravenous insulin, but perhaps at the expense of a higher risk of hypoglycaemia. 
In a single centre pilot study, 25 acute ischaemic stroke patients were randomised to insulin 
sliding scale approach or standard management [29]. Sliding scale insulin therapy 
significantly reduced blood glucose throughout 48-hour treatment. Stability of blood glucose 
within a pre-defined range was achieved with only one possible adverse event related to 
hypoglycaemia. Although not adequately powered to assess outcome, no significant 
differences in mortality or disability were observed between the two groups. In another study 
on 40 ischaemic stroke patients with onset <24 h ago, an intensive intravenous insulin 
infusion protocol, with the aim of reaching and maintaining blood glucose levels between 
4.44 mmol/L and 6.11 mmol/L, effectively lowered blood glucose levels as compared to 
insulin subcutaneously if concentrations were above 11.10 mmol/L [30]. Hypoglycaemic 
events were five times more common (but with few symptomatic events) in patients treated 
intensively whereas severe hyperglycaemia was five times more frequently associated with 
conventional treatment. In addition to the increased risk of manageable hypoglycaemic events, 
the authors concluded that intensive insulin treatment imposes considerable strain on both 
patients and caregivers. A highly motivated and trained staff seems essential, limiting 
feasibility outside of specialty care settings [30].  
 Despite the absence of clear evidence from interventional studies, current guidelines 
propose to manage hyperglycaemia in acute stroke. The main reason is that several reports 
provide reasonable evidence that persistent elevations of blood glucose levels are associated 
with neurological worsening. Nevertheless, most recommendations are prudent. Indeed even 
if experts concluded that the level of hyperglycaemia that previously mandated emergency 
treatment in the setting of stroke was too high, most of them considered that a reasonable 
approach would be to initiate insulin treatment among patients with a blood glucose level 
>11.10 mmol/L, although this remain a matter of controversy (see below). However, close 
monitoring of glucose concentrations with adjustment of insulin doses to avoid 
hypoglycaemia is recommended. Simultaneous administration of glucose and potassium also 
may be appropriate [31].  
 
3. IATROGENIC HYPOGLYCAEMIA AND STROKE 
 
 Hypoglycaemia is a common complication of the use of glucose-lowering agents in 
diabetic patients and its symptoms may mimic those of a stroke, which may cause problems 
regarding the clinical evaluation of patients admitted in stroke units. The reason why 
thresholds proposed in guidelines to initiate insulin therapy remain so “comfortable” is that 
severe hypoglycaemia may occur if the blood glucose targets are too strict. However, if 
glucose management is to be undertaken, this should be instituted while there is still 
salvageable tissue and the glucose reduction must be substantial. As already mentioned, 
intensive intravenous insulin may be more effective than GKI infusions. Any way, both 
interventions carry a risk of hypoglycaemia and any proposed intervention must balance 
efficacy/safety ratio as well as the convenience of glycaemic control. Indeed, in clinical 
practice, it is a real challenge to obtain near normoglycaemia with an aggressive management 
of hyperglycaemia without experiencing any hypoglycaemic event. A pilot study assessed the 
feasibility of early intravenous insulin in patients with post stroke hyperglycaemia (admission 
glucose concentration : 9.4–22.2 mmol/L). Across 24 patients, there was a substantial 
decrease in glucose level (from 14.7 ± 4.9 mmmo/L pre-intervention to 7.3 ± 1.1 mmol/L 
post-intervention) with an incidence of symptomatic hypoglycaemia episodes of 21% 
[29].With no control group, it is difficult to comment on how much of this change can be 
attributed to natural history of post-stroke hyperglycaemia rather than specific intervention. 
Based on these pilot data, the latter group have completed a larger randomised controlled trial. 
The recently published Treatment of Hyperglycaemia in Ischaemic Stroke (THIS) study 
randomised a predominantly diabetic cohort to intravenous insulin for 72 h or usual care 
(subcutaneous insulin) [32]. In this study, aggressive glucose management achieved better 
glycaemic control (mean difference in glucose concentration averaging 3.7 mmol/L). 
However, this was at the cost of increased rate of hypoglycaemia (12 episodes versus 0 
episodes). Clearly the limiting factor of an intensive management of hyperglycaemia in acute 
stroke is the risk of hypoglycaemia, which may also be deleterious for the brain [14,15]. 
Nevertheless, in available studies, it is difficult to link poor outcome after stroke and the 
occurrence of treatment-induced hypoglycaemia.  
 Because hypoglycaemia may produce neurological signs that mimic ischemic stroke 
and because hypoglycaemia itself may lead to brain injury, prompt measurement of the 
plasma glucose concentration and rapid correction of a low serum glucose level are important. 
Current guidelines pointed out that hypoglycaemia should be treated in patients with acute 
ischemic stroke (class I, level of evidence C) [31]. The goal is to restore normoglycaemia but 
excessive post-hypoglycaemia elevation of blood glucose levels should be avoided. 
 
4. LESSONS FROM CONTINUOUS GLUCOSE MONITORING 
 Most of the actual data are obtained by research groups that have used a single time 
point measure of blood glucose to define glycaemic control. However, this method can not 
precisely evaluate the severity and the duration of hyperglycaemia [33]. The development of 
continuous glucose monitoring system (CGMS) with a subcutaneous sensor device has 
provided a novel tool to record interstitial glycaemic kinetics [33]. GGMS revealed that 
normoglycaemia was only achieved 22% of the time in diabetic/non diabetic ICU patients 
[34] and that early and frequent hyperglycaemia occurred in non-diabetic patients with acute 
coronary syndromes [35]. Recent evidence suggests that continuous monitoring of glucose 
levels may help to signal glycaemic excursions and eventually to optimize insulin titration in 
the ICU [36]. 
 Using this technology, Baird et al performed a pilot study in which they aimed to 
directly address the relationship between stroke outcome and contemporaneous glycaemia 
[37]. This trial enrolled 25 subjects within 24 hours of ischaemic stroke symptoms. Multiple 
regression analysis indicated that both mean CGMS and blood glucose levels ≥7 mmol/L 
were independently associated with increased final infarct volume change. The conclusion 
was that there is an urgent need to study normalization of blood glucose after stroke. Later on, 
Allport et al [38] used CGMS device in 59 patients with acute hemispheric ischaemic stroke. 
Patients were prospectively studied regardless of medication, admission plasma glucose value, 
and diabetes status. On admission 36% of patients had preexisting diabetes. At the earliest 
analyzed time point of 8 h from stroke onset, 50% of non-diabetic subjects and 100% of 
diabetic patients were hyperglycaemic (≥7 mmol/L). This early-phase hyperglycaemia was 
followed by a decrease in glucose level 14–16 h post-stroke when only 11% of non-diabetic 
and 27% of diabetic patients were still hyperglycaemic. However, a late hyperglycaemic 
phase 48–88 h post-stroke was observed in 27% of non-diabetic and 78% of diabetic patients. 
Thirty-four percent of non-diabetic and 86% of diabetic patients were hyperglycaemic for at 
least a quarter of the monitoring period. Multivariate regression analysis demonstrated that 
diabetes, insular cortical ischaemia, and increasing age independently predicted higher 
glucose values. Thus post-stroke hyperglycaemia is common and rather prolonged despite 
treatment based on current guidelines. There are early and late hyperglycaemic phases in non-
diabetic as well as diabetic patients. Treatment protocols with frequent glucose measurement 
and intensive glucose-lowering therapy for a minimum of 72 h post-stroke need to be 
evaluated. With the recent improvement of glucose monitoring system [36], it will be 
probably easier to manage post-stroke hyperglycaemia in a more effective and safe manner in 
a near future [33]. 
 
5. PRACTICAL IMPLICATIONS REGARDING GLUCOSE MANAGEMENT 
DURING STROKE 
 Stroke is the second most common cause of death and major cause of disability 
worldwide. Advances have occurred in the prevention and treatment of stroke during the past 
decade [39].However, the lack of high quality evidence on the effects of blood glucose 
manipulation in acute stroke is reflected by the wide variation in current clinical practice. 
Similarly, local and international guidelines differ in recommendations for treatment of post-
stroke hyperglycaemia. Comparing guidance from the American Stroke Association [31], the 
UK Royal College of Physicians [40] and the European Stroke Organisation (ESO) [41], all 
agree that post-stroke hyperglycaemia is associated with poorer outcomes, that (major) 
hyperglycaemia should be prevented/treated and that iatrogenic hypoglycaemia must be 
avoided or promptly treated (Figure 1). However, there is no consensus on the frequency of 
glucose monitoring, thresholds for intervention or methods to achieve glucose control [42,43]. 
 According to the American Stroke Association [31], because evidence indicates that 
persistent hyperglycaemia ( > 7.8 mmol/L) during the first 24 hours after stroke is associated 
with poor outcomes,  lower plasma glucose concentrations than the commonly accepted 10-11 
mmol/L threshold (possibly > 7.8 to 10.3 mmol/L) probably should trigger administration of 
insulin. This approach is similar to the procedure in other acute situations accompanied by 
hyperglycaemia (recommendation class IIa, level of evidence C) [31]. However, the most 
recently revised guidelines of the European Stroke Organisation still suggest consideration of 
intervention if blood glucose concentration is greater than 10 mmol/L, provided that 
hypoglycaemia can be avoided [41].  
 In clinical practice the first step is to objective hyperglycaemia at the admission and in 
post-stroke state in a sufficiently accurate manner to evaluate its severity and duration. 
Intravenous insulin therapy and frequent blood glucose control to adapt insulin delivery are 
required. A number of approaches to acute glycaemic control have been described and there is 
presently no consensus as to the optimal intervention. Glucose-potassium-insulin (GKI)-based 
regimes infuse a solution of predetermined concentrations of glucose, insulin and potassium 
with peripheral glucose monitoring to guide the rate of infusion. An alternative approach is 
that of a ‘sliding scale’ insulin administration, wherein the infusion uses a rapidly acting 
insulin preparation. Proponents of GKI state that this approach is more ‘physiological’ and 
less prone to dangerous extremes of blood sugar. However, the frequent changes of infusion 
required to maintain glucose is time consuming. Alternatively, treating hyperglycaemia with 
intravenous insulin therapy only (without concomitant glucose infusion) requires frequent 
control of blood glucose concentrations to adapt rates of insulin in order to avoid 
hypoglycaemia. Ideally, clinicians should not infuse any glucose solution during the 
management of such patients (except to correct hypoglycaemia) in order to avoid acute 
hyperglycaemia, which may be deleterious for the injured brain [7]. Even if CGMS has only 
been used to carefully evaluate post-stroke hyperglycaemia yet, this technology will probably 
be interesting in the future to manage hyperglycaemia in stroke unit in a more effective and 




 The danger of post-stroke hyperglycaemia is well established, with numerous data 
confirming an association between hyperglycaemia and poor outcomes, including in patients 
treated with thrombolysis. However, although there is compelling evidence that 
hyperglycaemia has an effect on stroke outcome, debate continues as to whether the effect is 
independent of the influence of diabetes or initial stroke severity. The aetiology of 
hyperglycaemia and the pathophysiology that underlie detrimental effects of hyperglycaemia 
remain unclear. A distinction between unknown diabetes and non diabetic hyperglycaemia 
seems important as prognosis and effect of intervention have been shown to differ in these 
two groups. When one attempts to treat hyperglycaemia, care should be taken to avoid rapid 
fluid shifts, electrolyte abnormalities, and hypoglycaemia, all of which can be detrimental to 
the brain. Patients with critical brain disease should have frequent glucose monitoring 
because (severe) hyperglycaemia and even modest hypoglycaemia may be detrimental. The 
safety and efficacy of intravenous insulin therapy in patients with critical brain disease have 
not been well studied. Careful use of insulin infusion protocols appears advisable, but 
maintenance of strict normoglycaemia cannot be recommended in this population because of 
a too high risk of hypoglycaemia. Rigorous studies must be conducted to assess the value of 
insulin therapy and to determine the optimal blood glucose targets in patients with the most 
common acute vascular insults. Finally, experts have to propose clear guidelines feasible in 
clinical practice. One of the key successes will probably be the ability to check continuously 
glucose to adapt insulin therapy on time. This approach needs CGMS devices with good 
accuracy and short lag time in order to minimize the risk of both stroke-induced 
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 Figure 1 : Illustration of the interrelationships between stroke and glucose control. A : 
Deleterious effects of post-stroke hyperglycaemia. B : Deleterious effects of iatrogenic 
hypoglycaemia. C : Potential benefit of Continuous Glucose Monitoring System (CGMS) and 
Intensive Insulin Therapy (IIT) driven by CGMS. GKI : Glucose-Potassium-Insulin.  
